Buscar
Mostrando ítems 21-30 de 129
CHRNA7 triplication associated with cognitive impairment and neuropsychiatric phenotypes in a three-generation pedigree
(Nature Publishing Group, 2015)
CHRNA7 triplication associated with cognitive impairment and neuropsychiatric phenotypes in a three-generation pedigree
(Nature Publishing Group, 2021)
The genomic landscape across 474 surgically accessible epileptogenic human brain lesions
(2022)
Understanding the exact molecular mechanisms involved in the etiology of epileptogenic pathologies with or without tumor activity is essential for improving treatment of drug-resistant focal epilepsy. Here, we characterize ...
Evaluation of the bio-protection mechanism in diffusive exchange permeable reactive barriers for the treatment of acid mine drainage
(2019-03-10)
This research studied the bio-protection mechanism based on chemical gradients in diffusive exchange permeable reactive barriers, evaluating the thickness of the reactive layers in the treatment of concentrated acid mine ...
Chromosomal microarray analysis in the genetic evaluation of 279 patients with syndromic obesity
(Biomed Central Ltd, 2018)
Background: Syndromic obesity is an umbrella term used to describe cases where obesity occurs with additional phenotypes. It often arises as part of a distinct genetic syndrome with Prader-Willi syndrome being a classical ...
A adesão das ações educativas realizadas por enfermeiros aos pacientes acometidos por hipertensão arterial sistêmica: uma revisão integrativa
(Universidade Federal de Minas GeraisUFMG, 2015-06-26)
This work aims to identify if the educational activities performed by nurses are effective for treatment adherence of patients with systemic hypertension. An integrative literature review was conducted comprised of six ...
Evaluation of the prognostic potential of EGFL7 in pilocytic astrocytomas
(2021-02-01)
Pilocytic astrocytoma (PA) is the most frequent solid neoplasm in childhood. It has a good 5-year overall survival (90% in childhood and 52% in adults). However, up to 20% of patients experience residual tumor growth, ...